Urology

African-American men with low-risk prostate cancer have a significantly increased 10-year cumulative incidence of disease progression and definitive treatment than non-Hispanic White men, according to a study published in the Nov. 3 issue of the Journal of the American Medical Association. Rishi Deka, Ph.D., from the VHA San Diego Health Care System in La Jolla, and...

FRIDAY, Nov. 6, 2020 — A ‘watchful waiting’ approach to care may be safe for Black Americans with low-risk prostate cancer, a new study suggests. Black patients are less likely than whites to be offered watchful waiting, also called active surveillance. This may be because compared to whites, Black men are more likely to have...

According to the American Cancer Society, approximately 1 in 9 men will develop prostate cancer at some point during their lifetime. Nearly 100% of men who are diagnosed with early-stage, localized prostate cancer will survive the disease, but this figure drops dramatically to only a 32% five-year survival among men who are diagnosed with advanced-stage...

Compared to all other racial and ethnic groups, Black men are significantly more likely to be diagnosed with prostate cancer and to die as a result of the disease.  Despite evidence that this uneven burden of morbidity and mortality is due in part to race-based variations in tumor biology and underlying disease mechanisms, prostate cancer...

Prostate cancer is the most common cancer among American men. The American Cancer Society estimates that in 2020, nearly 200,000 men will be diagnosed with prostate cancer and more than 33,000 will die from the disease in the United States alone. A disproportionate number of these deaths will occur among men from racial/ethnic minority groups, particularly...

In the united states, there will be approximately 192,000 cases of prostate cancer in 2020 and 33,000 deaths. 1 Clinical trials are often sought in advanced cases of cancer when standard therapy is not working or not an option. Clinical trials have the benefit of providing patients with access to therapies not routinely available. Immunotherapy...

African Americans have the highest incidence of prostate cancer, yet participation in clinical trials related to prostate cancer remains low.  The inclusion of African American men in prostate cancer trials decreased from 11.3% in 1995 to 2.8% in 2014. Lab Miscalculation  A study published in JAMA Oncology  reviewed a list of prostate cancer clinical trials...

Investigators report that although 22% of prostate cancer diagnoses take place in non-Hispanic Black men, more than 96% of participants in prostate cancer clinical trials are non-Hispanic white men. That was the conclusion published in Cancer Epidemiology, Biomarkers, and Prevention. Furthermore, enrollment of African American men in prostate cancer studies since the year 1995 has...

Surgical approach is not associated with intermediate-term decision regret following radical prostatectomy, according to a study published in the March issue of The Journal of Urology. Martin Baunacke, M.D., from Technische Universität Dresden in Germany, and colleagues evaluated intermediate-term decision regret after open (532 patients) and robot-assisted (404 patients) radical prostatectomy (2008 to 2013). The analysis...